About
Technology
Issues
FAQ
Links
Official Page
Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.